Xtandi

Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Fierce Pharma
Merck
Pfizer
immuno-oncology
M&A
Keytruda
Prevnar
Ibrance
Xeljanz
Xtandi
Flag link:
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
Motley Fool
cancer
oncology
Pfizer
Ibrance
breast cancer
Xtandi
prostate cancer
Bavencio
bladder cancer
Merkel cell carcinoma
lorlatinib
metastatic non-small cell lung cancer
talazoparib
metastatic breast cancer
Flag link:
Pfizer, Astellas peg Xtandi expansion on PROSPER data
Pfizer, Astellas peg Xtandi expansion on PROSPER data
Biopharma Dive
Pfizer
Astellas
Xtandi
prostate cancer
Flag link:
Patent setback could sting J&J prostate cancer franchise
Patent setback could sting J&J prostate cancer franchise
Biopharma Dive
patents
JNJ
prostate cancer
Zytiga
Xtandi
Astellas
Flag link:
With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK
With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK
Endpoints
Pfizer
JNJ
patents
Zytiga
Xtandi
prostate cancer
apalutamide
Flag link:
New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi
New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi
Endpoints
Pfizer
Astellas
clinical trials
Xtandi
prostate cancer
Flag link:
Astellas, Pfizer scrap a PhIII breast cancer study using Xtandi; New $30M fund will back Israeli biotech startups
Astellas, Pfizer scrap a PhIII breast cancer study using Xtandi; New $30M fund will back Israeli biotech startups
Endpoints
Astellas
Pfizer
breast cancer
clinical trials
Xtandi
Israel
biotech
Flag link:
Here's Why the Best Is Yet to Come for Pfizer Inc.
Here's Why the Best Is Yet to Come for Pfizer Inc.
Motley Fool
Pfizer
Eucrisa
Xtandi
Inflectra
Flag link:
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
Fierce Pharma
Pfizer
Xtandi
Medivation
Flag link:
Astellas inks biomarker deal to pinpoint Xtandi patients
Astellas inks biomarker deal to pinpoint Xtandi patients
BioPharma Dive
Astellas
Xtandi
biomarkers
patients
tumor profiles
Flag link:
The 3 Biggest Risks for Pfizer in 2017
The 3 Biggest Risks for Pfizer in 2017
Motley Fool
Pfizer
Xtandi
competition
patents
Lyrica
Celebrex
Flag link:
Pfizer's Xtandi fails in progression trial vs J&J's Zytiga
Pfizer's Xtandi fails in progression trial vs J&J's Zytiga
Yahoo/Reuters
Xtandi
Pfizer
JNJ
Zytiga
prostate cancer
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals
Flag link:
Is This Pfizer's Next Mega-Blockbuster Cancer Drug?
Is This Pfizer's Next Mega-Blockbuster Cancer Drug?
Motley Fool
Pfizer
Medivation
Xtandi
avelumab
Merck KGaA
Ibrance
Flag link:
Pfizer: Hospira Is Future; Xtandi Is Today's Meal
Pfizer: Hospira Is Future; Xtandi Is Today's Meal
Yahoo/GuruFocus
Pfizer
Hospira
Xtandi
M&A
Medivation
Flag link:
Key FDA Decisions and Trial Results Coming in the Next 2 Months
Key FDA Decisions and Trial Results Coming in the Next 2 Months
24/7 Wall St
FDA
clinical trials
Array Biopharma
binimetinib
Mast Therapeutics
Novavax
RSV F vaccine
Threshold Pharmaceuticals
tarloxotinib
Cerulean Pharma
Vertex Pharmaceuticals
Orkambi
Exelixis
cabozantinib
Cobimetinib
Medivation
Xtandi
Celldex
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
cabozantinib
Cobimetinib
Exelixis
Medivation
Xtandi
Celldex Therapeutics
glemba
Palatin
bremelanotide
CRLX101
Cerulean Pharma
Anthera Pharmaceuticals
Flag link:
Ibrance and Xtandi Could Be in the Top 10 Oncology Drugs by 2021
Ibrance and Xtandi Could Be in the Top 10 Oncology Drugs by 2021
Market Realist
Ibrance
Xtandi
oncology
Pfizer
Medivation
breast cancer
prostate cancer
Flag link:
How Mylan And Pfizer Could Cause A Major Biotech Backlash
How Mylan And Pfizer Could Cause A Major Biotech Backlash
Forbes
Mylan Labs
Pfizer
EpiPen
Xtandi
Flag link:
What Pfizer Gets in Its $14 Billion Medivation Deal
What Pfizer Gets in Its $14 Billion Medivation Deal
Motley Fool
Pfizer
Medivation
M&A
Xtandi
prostate cancer
talazoparib
pidilizumab
Flag link:

Pages